2Fine HA,Wen PY,Maher EA ,et al. Phase trail of thalidomide and carmustine for patients with recurrent high-grage gliomas[J].J Clin Oncol, 2003,21 : 2299-2304.
4Folkman J. Role of angiogenesis in tumor growth and metastasis.Semin Oncol,2002,29(6 Suppl 16) : 15-18.
5Huang X, Wong MK, Zhao Q, et al. Soluble recombinant endostatinpurified from Escherichia coli: antiangiogenic activity and antitumor effect. Cancer Res,2001,61(2): 478-481. Erratum in:Cancer Res, 2001,61 ( 15 ) : 5956. Cancer Res, 2001,61 (10) :4297.
6Li B, Wu XY, Zhou H, et al. Acid-induced unfolding mechanism of recombinant human endostatin. Biochemistry, 2004, 43 (9) :2550-2557.
7Eder JP Jr, Supko JG, Clark JW, et al. Phase Ⅰ clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol, 2002,20(18) : 3772-3784.
8Kulke M, Bergsland E, Ryan DP, et al. A phase Ⅱ , open-label,safety, pharmacokinetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors. Proc ASCO,2003,22: 958a.
9Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase Ⅲ randomized trial comparing three platinum-based doublets in advanced nonsmall cell lung cancer. J Clin Oncol,2002,20(21) : 4285-4291.
10Gebbia V, Galetta D, Caruso M, et al. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine fol lowed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage Ⅲ B-Ⅳ non small cell lung carcinoma: a prospective randomized phase Ⅲ trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer,2003,39(2) :179-189.
1Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA CancerJ Clin, 2011, 61(2): 69-90.
2Hgg WD, Hussaln MH, GulleyJL, et al. A double-blind random- ized crossover study of oral thalidomide versus placebo for andro- gen dependent prostate cancer treated with intermittent androgen ablation[J].J Urol, 2009, 181(3): 1104-1113.
3Lee SM, Rudd R, Woll PJ, et al. Randomized double-blind place- bo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer[J]. J Clin Oncol, 2009, 27(31): 5248-5254.
4Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplat- in-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361 (10): 947-957.
5Higgins JPT, Green S. Cochrane Handbook for Systematic Review of Inerventions Version 5 chrane Collaboration, 2011 1. 0(updated March 2011). The Co- www.cochrane-handbook.org.
6Merino M, Pinto A, Gonzalez R, et al. Antiangiogenic agents and en- dothelin antagonists in advanced castration resistant prostate cancer [J]. EurJ Cancer, 2011, 47(12): 1846-1851.
7Jazieh AR, Komrokji R, Gupta A, et al. Phase II trial of thalido- mide, irinotecan and gemcitabine in chemonaive patients with ad- vanced non-small cell lung cancer[J]. Cancer Invest, 2009, 27(9): 932-936.
8Dudek AZ, Lesniewski-Kmak K, Larson T, et al. Phase IItrial of neoadjuvant therapy with carboplatin, gemcitabine plus thalido- mide for stages IIB and II non-small cell lung cancer[J]. J Thorac Oncol, 2009, 4(8): 969-975.
9Paravar T, Lee DJ. Thalidomide: mechanisms of action[J]. Int Rev Immunol, 2008, 27(3): 111-135.
10Ruegg C, Peters S. Thalidomide in small cell lung cancer: wrong drug or wrong disease[J].? J Natl Cancer Inst, 2009, 101(15): 1034-1035.
